10-Q: BioLargo Inc. Reports Strong Revenue Growth in Q2 2024 Driven by Consumer Product Sales

BioLargo Inc. saw a significant increase in revenue during the second quarter of 2024, primarily driven by sales of its private-label pet odor control product.

Summary

• BioLargo, Inc. reported a substantial revenue increase of 247% for the three months and 88% for the six months ended June 30, 2024, compared to the same periods in 2023.
• This growth was largely due to increased sales of the 'Pooph' branded pet odor control product, which accounted for 70% and 78% of the company's total revenue for the respective periods.
• The company's product revenue increased by 272% and 95% for the three and six months ended June 30, 2024, respectively, while service revenue decreased by 5% for both periods.
• BioLargo generated $330,000 in net cash from operating activities for the six months ended June 30, 2024.
• The company's net loss for the three and six months ended June 30, 2024, was $780,000 and $1,555,000, respectively, a decrease compared to the losses of $1,626,000 and $2,120,000 for the same periods in 2023.
• BioLargo's cash and cash equivalents totaled $4,765,000 as of June 30, 2024, with total current assets of $7,110,000 and working capital of $4,098,000.
• The company continues to rely on one major customer for a significant portion of its revenue and is actively seeking additional investment capital to fund its business plans and new technologies.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there is strong revenue growth, the company is still operating at a loss and is heavily reliant on a single product. The need for further capital raises and the material weakness in internal controls are also concerning. The company has a number of promising technologies, but the path to profitability is not yet clear.

Positives

• Significant revenue growth driven by the success of the 'Pooph' branded product.
• Positive net cash flow from operating activities for the first six months of 2024.
• Decreased net losses compared to the same periods in the previous year.
• Strong cash position with $4,765,000 in cash and cash equivalents.
• The company has a substantial pipeline of potential projects for its PFAS treatment technology.
• The company has secured channel partner agreements with several sales representative organizations ensuring coverage for most of the continental United States.

Negatives

• High reliance on a single customer for a majority of revenue.
• Continued net losses despite revenue growth.
• Ongoing need for additional investment capital to fund operations and new technologies.
• A material weakness in internal controls over financial reporting.
• The company's South Korean joint venture has struggled to gain a foothold.
• The sales cycle for municipal and industrial water treatment equipment is long.

Risks

• The company's ability to continue as a going concern is dependent on increasing revenues, generating cash from operations, or securing additional financing.
• The company is highly reliant on one customer for a majority of its revenue, which poses a significant risk.
• The company's success is dependent on the continued success of the 'Pooph' branded product, which is outside of their direct control.
• The company faces challenges in scaling up its operations and hiring qualified staff to meet growing demand.
• The company's internal controls over financial reporting have a material weakness.
• The company's South Korean joint venture has struggled to gain a foothold.

Future Outlook

BioLargo anticipates needing further investment capital to fund its business plans and investments in new technologies. The company expects to continue to sell securities to ensure available working capital. The company is focused on demonstrating its technologies efficacy in first demonstration projects, trials, and early customer deployments with the understanding that this early success can be leveraged to secure larger and more numerous subsequent projects. The company is also focused on marketing its PFAS expertise and its technology by presenting at industry events and conferences around the country, cultivating its status as thought leaders in the space.

Management Comments

• Every member of our team including PhD scientists, engineers, and entrepreneurs has a passion for seeking new, never-before-seen innovations that can make life better around the world.
• We care about safeguarding the environment and human health for future generations.
• We care about making technologies that are affordable and flexible enough to be accessed around the world.
• We care about being the best at what we do creating best-in-class technologies to solve big, tough cleantech challenges.

Industry Context

The report highlights BioLargo's focus on addressing critical environmental issues such as PFAS contamination, water pollution, and air quality, which are significant concerns in the cleantech industry. The company's development of innovative technologies like the AEC, AROS, and AOS positions it to capitalize on the growing demand for sustainable solutions. The company's battery technology also aligns with the global shift towards renewable energy and the need for efficient energy storage solutions. The company's focus on the medical field with its Bioclynse product also positions it to capitalize on the growing demand for advanced medical solutions.

Comparison to Industry Standards

• BioLargo's revenue growth of 247% in Q2 2024 is significantly higher than the average growth rate for many companies in the environmental technology sector, although this is largely driven by a single product.
• The company's focus on PFAS removal with its AEC technology aligns with the increasing regulatory pressure and market demand for effective PFAS treatment solutions, putting it in competition with companies like Evoqua Water Technologies and Xylem, who also offer PFAS solutions.
• BioLargo's development of a sodium-based battery technology with its Cellinity product places it in competition with companies like QuantumScape and Solid Power, who are developing advanced battery technologies, although BioLargo's focus is on long-duration stationary storage.
• The company's Bioclynse wound irrigation solution competes with established medical device companies like Stryker and Medtronic, who offer similar products, but BioLargo claims superior performance in biofilm disruption and inhibition.
• The company's engineering services division, BLEST, competes with other environmental engineering firms like AECOM and Jacobs, but has a focus on supporting BioLargo's internal projects.

Management Changes

Stakeholder Impact

• Shareholders: The company's financial performance and need for additional capital raises may impact shareholder value.
• Employees: The company's growth and development of new technologies may create new opportunities for employees.
• Customers: The company's products and services aim to address critical environmental and health issues, potentially benefiting customers.
• Suppliers: The company's growth may lead to increased demand for raw materials and services from suppliers.
• Creditors: The company's financial performance and ability to secure additional financing may impact its ability to meet its debt obligations.

Next Steps

• Continue to increase revenues and generate cash from operations.
• Convert assets such as accounts receivable into cash.
• Reduce ongoing cash obligations by curtailing portions of operations if necessary.
• Focus on demonstrating the efficacy of the AEC technology in first demonstration projects.
• Market PFAS expertise and technology at industry events.
• Engage in discussions with credible distribution partners for water treatment technologies.
• Continue to develop and test prototype batteries for the Cellinity technology.
• Develop partnerships with large distributors for the Bioclynse product.
• Hire additional qualified sales engineers to assist in bidding and specification efforts for new projects.

Key Dates

Keywords

BioLargo, revenue growth, Pooph, odor control, PFAS, water treatment, AEC, AROS, AOS, battery technology, Cellinity, Bioclynse, financial results, operating loss, net loss, capital raise, BLEST, ONM Environmental, Clyra Medical, BETI